Tiny Gene Regulators Show Promise Against the Deadliest Childhood Brain Tumors

Pediatric diffuse high-grade glioma grade 4, the most aggressive malignant primary brain tumor of childhood, remains essentially incurable, with five-year survival below ten percent. Unlike many adult cancers, these tumors rarely carry a long list of recurrent genetic mutations that could be drugged directly. Instead, their ferocity appears to arise largely from epigenetic changes—alterations that switch genes on or off without touching the DNA sequence itself. A new study published in Pediatric Research by Dikla Rogachevsky, Michal Yalon, Ruty Mehrian-Shai, and Amos Toren of Tel Aviv University and Sheba Medical Center now shines a spotlight on two small epigenetic regulators, microRNAs miR-34a and miR-34c, and shows that restoring them can strip away several of the malignant behaviors that make these tumors so lethal.

MicroRNAs are tiny single-stranded RNA molecules, roughly twenty-two nucleotides long, that act as post-transcriptional brakes on gene expression. By binding to messenger RNAs, a single microRNA can simultaneously dampen dozens of target genes, which makes them powerful coordinators of cellular programs. The miR-34 family, which includes miR-34a and miR-34c, is positively regulated by the tumor suppressor p53 and is well established as a metastasis-suppressing force in many cancers, including adult glioblastoma. Because pediatric high-grade gliomas frequently harbor inactivating mutations in the TP53 gene, the researchers suspected that the miR-34 axis might be crippled in these tumors—but until now, its role had never been examined.

The team worked with two cell line models derived from molecularly distinct patients. SF188 came from a biopsy of an eight-year-old boy, while KNS42 was established from an aggressive tumor resected from a sixteen-year-old male and carries the distinctive H3F3A G34V histone mutation. Both lines express glial markers and harbor point mutations in p53. Using quantitative PCR, the researchers found that both miR-34a and miR-34c were significantly downregulated in the tumor cell lines compared with normal human astrocytes. They then turned to a public tumor dataset, GEO accession GSE63319, comprising eleven pHGG-4 cases and four age-matched controls, and found that mean miR-34c expression was markedly reduced in the patient tumors, while miR-34a was low in a subset of samples.

With the suppressors confirmed to be missing, the researchers reintroduced them. They transfected the cells with synthetic miR-34a or miR-34c mimics, or with a scrambled oligonucleotide as a negative control, and measured the consequences. The results were striking. Ectopic upregulation of either microRNA reduced cell viability by roughly forty percent in KNS42 cells and sixty percent in SF188 cells. Colony formation assays, in which single cells must proliferate into visible colonies of at least fifty cells over several weeks, told the same story: colony formation fell by 63 to 69 percent in KNS42 cells and by 54 to 62 percent in SF188 cells, depending on which microRNA was restored.

The most clinically meaningful effects concerned the tumor’s infiltrative behavior, the property that makes complete surgical removal nearly impossible. In scratch wound healing assays, restoring miR-34a or miR-34c inhibited gap closure in SF188 cells by 29 and 46 percent respectively. In transwell migration assays, miR-34a slashed KNS42 cell migration by 73 percent, while miR-34c cut it by 42 percent. Invasion through a basement membrane extract was similarly blunted: miR-34a reduced invasiveness by 56 percent in SF188 and 57 percent in KNS42 cells, and miR-34c by 43 and 46 percent. In other words, both microRNAs acted as broad brakes on the very behaviors that drive tumor spread through a child’s brain.

To understand how these small RNAs achieved such wide-ranging effects, the team mapped their impact on the molecular machinery of survival and proliferation. Both microRNAs downregulated the anti-apoptotic gene BCL-2 and upregulated the pro-apoptotic genes PUMA and, in some cases, BAX and BIM, while inducing the cell cycle arrest gene P21. They also suppressed CDK6, a driver of cell cycle progression, and reduced the potent oncogenes N-MYC and C-MYC, though in a pattern that differed between the two microRNAs and the two cell lines. Notably, these targeting patterns diverged from those previously reported in other cancers, underscoring that the miR-34 family operates through non-redundant, context-dependent pathways in pediatric glioma cells.

Perhaps the most surprising finding involved p53 itself. Although both cell lines carry point mutations in TP53, immunofluorescence staining with conformation-specific antibodies revealed that the mutant protein predominantly adopts a mutant shape in untreated cells—and that restoring either miR-34a or miR-34c shifted the protein toward its wild-type conformation in both cell lines. This conformational rescue was accompanied by a sharp drop in SIRT1, an NAD-dependent deacetylase that normally restrains p53 activation. SIRT1 mRNA was three to 3.6-fold elevated in the tumor cells relative to normal astrocytes, and both microRNAs cut its mRNA levels by roughly half while reducing protein expression by 50 to 85 percent. Together, these changes suggest that the miR-34 family can partially reactivate the cell’s central tumor-suppressive circuitry even in tumors where the guardian gene itself is mutated.

The researchers then probed the epithelial–mesenchymal transition, or EMT, the cellular program by which tumor cells lose adhesion and polarity and gain migratory, invasive, and stem-like properties. In central nervous system tumors, EMT-like mechanisms mirror those of epithelial cancers and are thought to underpin much of pHGG-4 aggressiveness. Both microRNAs targeted multiple EMT mediators, including the NOTCH1 and NOTCH2 receptors, the transcriptional repressor SNAIL1, the interleukin-6 receptor and its downstream effector STAT3, and the receptor tyrosine kinase C-MET, whose expression fell by up to 80 percent at the mRNA level. The team also detected nMET, a truncated nuclear C-MET fragment associated with malignant progression, and found it reduced as well. Downstream, miR-34c dampened phosphorylated FAK in both cell lines, while miR-34a did so only in SF188 cells. Meanwhile, the epithelial marker CDH1, encoding E-cadherin, was restored up to four-fold in KNS42 cells, and the stemness markers CD133 and NESTIN fell by 32 to 71 percent across both models.

A recurring theme throughout the study is that the two microRNAs, while producing similar phenotypic outcomes, achieved them through overlapping but non-identical molecular routes that varied between cell lines. miR-34c emerged as the broader suppressor, hitting N-MYC, C-MYC, SIRT1, nMET, and pFAK across both models, whereas miR-34a showed a particularly strong inhibitory effect on the migratory behavior of the H3F3A G34-mutated KNS42 line. This cell line dependence reinforces the study’s central message: epigenetic dysregulation, rather than a short list of recurrent genetic alterations, is a central engine of pHGG-4 aggressiveness, and correcting it can dismantle multiple malignant programs at once.

The findings also arrive amid a cautious resurgence of interest in microRNA therapeutics. The first-in-human trial of MRX34, a liposomal miR-34a mimic tested in non-central nervous system malignancies, produced encouraging antitumor responses before being halted over immune-mediated adverse events. Challenges such as delivery to brain tissue, variable expression, and immune safety remain formidable. Still, by demonstrating that two naturally occurring tumor suppressors can simultaneously curb survival, proliferation, migration, invasion, and stemness in an otherwise untreatable pediatric cancer, this work lays a rational foundation for miR-34-based therapeutic strategies—and offers a glimmer of hope for children facing one of medicine’s most devastating diagnoses.

Subject of Research: The role of the microRNAs miR-34a and miR-34c as tumor suppressors regulating aggressiveness in pediatric high-grade glioma grade 4

Article Title: The potential role of miR-34a and miR-34c in the regulation of pediatric high-grade glioma 4 aggressiveness

Article References: Rogachevsky, D., Yalon, M., Mehrian-Shai, R., & Toren, A. (2026). The potential role of miR-34a and miR-34c in the regulation of pediatric high-grade glioma 4 aggressiveness. Pediatric Research. https://doi.org/10.1038/s41390-026-05518-y

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05518-y

Keywords: pediatric high-grade glioma, miR-34a, miR-34c, microRNA, epigenetics, p53, SIRT1, EMT, C-MET, tumor suppressor, glioblastoma, miRNA therapeutics